K-numberK250630
Device nameNitrile Powder-Free Exam Gloves with Hyaluronic Acid, and tested for Use with Chemotherapy Drugs, Opioid Fentanyl Citrate, Simulated Gastric Acid and Xylazine in Fentanyl Citrate
ApplicantBasic Medical Technology, Inc.
Product codeLZA
Device classClass I
Decision dateMay 22, 2025
DecisionSubstantially Equivalent
Regulation880.6250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The device is a non-sterile, powder-free, blue nitrile examination glove with an inner hyaluronic acid coating, available in sizes XS through XXL. It is designed for medical examination purposes to prevent contamination between patient and examiner, and has been tested for resistance to permeation by chemotherapy drugs, fentanyl citrate, simulated gastric acid, and xylazine.

Technological characteristics

The gloves are ambidextrous with beaded cuff, fingertip textured, made from synthetic nitrile latex, and feature an inner hyaluronic acid coating. They meet ASTM D6319-19 specifications with minimum tensile strength of 14 MPa before and after aging, minimum elongation of 500% before aging and 400% after aging, thickness of 0.05 mm minimum, and residual powder not exceeding 2 mg per glove.

Test standards cited

ASTM D6319-19 (Nitrile Examination Gloves for Medical Application), ASTM D6124-06 (Residual Powder on Medical Gloves), ASTM D5151-19 (Detection of Holes in Medical Gloves), ASTM D6978-05 (Assessment of resistance of Medical Gloves to Permeation by Chemotherapy Drugs), ISO 10993-23 (Primary Skin Irritation), ISO 10993-10 (Dermal Sensitization), and ISO 10993-11 (Systemic Toxicity).

Substantial equivalence argument

The proposed device is substantially equivalent because it is identical in material (nitrile), design features (ambidextrous, non-sterile, powder-free), dimensions, and biocompatibility profile to the predicate device K231365. Both devices are tested to the same permeation standards and meet identical physical property specifications. The addition of expanded chemotherapy drug testing and Xylazine/gastric acid claims does not raise new safety or effectiveness concerns, as these represent additional labeling claims supported by testing using established ASTM methods, without changing the device's fundamental design or performance characteristics.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →